ArticleInvestigational new drugs2015

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.

A Omlin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.